PURPOSE: National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol LTS-01 examines routine preventive care and cancer surveillance in long-term colorectal cancer (CRC) survivors previously treated in NSABP adjuvant trials. PATIENTS AND METHODS: Long-term CRC survivors (≥5 years) from five completed NSABP trials (Protocols C-05, C-06, C-07, R-02, and R-03) at 60 study sites were recruited and surveyed using preventive health care items from the National Health Interview Survey (NHIS). A 3:1 comparison cohort case-matched by age, sex, race, and education was created from the 2005 NHIS. Contingency tables and multivariate models were used to compare cohorts and determine predictors of preventive care and cancer surveillance. RESULTS: A total of 708 patients in protocol LTS-01 (681 patients with colon cancer, 27 patients with rectal cancer) completed the interview: 57.1% male, mean age 66.2 years (standard deviation=10.6), median survival 8 years. Patients in the LTS-01 protocol were more likely to have a usual source of health care (97.7% v 93.8%, P<.0001), have received a flu shot in the past 12 months (67.5% v 44.3%, P<.0001), and have undergone cancer screening by Pap smear (67.3% v 54.8%, P<.0001), mammogram (80.4% v 70.7%, P<.0001), and prostate-specific antigen test (84.5% v 74.5%, P<.0001) than patients in the NHIS cohort. For CRC surveillance, 96.5% of patients in protocol LTS-01 had a colonoscopy, 88.2% had a carcinoembryonic antigen test, and 66.4% had a computed tomography scan in the previous 5 years. Health insurance was the best predictor of cancer screening for all three methods (odds ratio=2.6 to 4.5). No factor was uniformly associated with CRC surveillance. CONCLUSION: This select population of long-term CRC survivors who participated in clinical trials achieved better routine preventive care and cancer screening than the general population and high rates of cancer surveillance.
PURPOSE: National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol LTS-01 examines routine preventive care and cancer surveillance in long-term colorectal cancer (CRC) survivors previously treated in NSABP adjuvant trials. PATIENTS AND METHODS: Long-term CRC survivors (≥5 years) from five completed NSABP trials (Protocols C-05, C-06, C-07, R-02, and R-03) at 60 study sites were recruited and surveyed using preventive health care items from the National Health Interview Survey (NHIS). A 3:1 comparison cohort case-matched by age, sex, race, and education was created from the 2005 NHIS. Contingency tables and multivariate models were used to compare cohorts and determine predictors of preventive care and cancer surveillance. RESULTS: A total of 708 patients in protocol LTS-01 (681 patients with colon cancer, 27 patients with rectal cancer) completed the interview: 57.1% male, mean age 66.2 years (standard deviation=10.6), median survival 8 years. Patients in the LTS-01 protocol were more likely to have a usual source of health care (97.7% v 93.8%, P<.0001), have received a flu shot in the past 12 months (67.5% v 44.3%, P<.0001), and have undergone cancer screening by Pap smear (67.3% v 54.8%, P<.0001), mammogram (80.4% v 70.7%, P<.0001), and prostate-specific antigen test (84.5% v 74.5%, P<.0001) than patients in the NHIS cohort. For CRC surveillance, 96.5% of patients in protocol LTS-01 had a colonoscopy, 88.2% had a carcinoembryonic antigen test, and 66.4% had a computed tomography scan in the previous 5 years. Health insurance was the best predictor of cancer screening for all three methods (odds ratio=2.6 to 4.5). No factor was uniformly associated with CRC surveillance. CONCLUSION: This select population of long-term CRC survivors who participated in clinical trials achieved better routine preventive care and cancer screening than the general population and high rates of cancer surveillance.
Authors: Jennifer Elston Lafata; Jan Simpkins; Lonni Schultz; Gary A Chase; Christine Cole Johnson; Marianne Ulcickas Yood; Lois Lamerato; David Nathanson; Greg Cooper Journal: Med Care Date: 2005-06 Impact factor: 2.983
Authors: Christopher E Desch; Al B Benson; Mark R Somerfield; Patrick J Flynn; Carol Krause; Charles L Loprinzi; Bruce D Minsky; David G Pfister; Katherine S Virgo; Nicholas J Petrelli Journal: J Clin Oncol Date: 2005-10-31 Impact factor: 44.544
Authors: N Wolmark; H S Wieand; D M Hyams; L Colangelo; N V Dimitrov; E H Romond; M Wexler; D Prager; A B Cruz; P H Gordon; N J Petrelli; M Deutsch; E Mamounas; D L Wickerham; E R Fisher; H Rockette; B Fisher Journal: J Natl Cancer Inst Date: 2000-03-01 Impact factor: 13.506
Authors: Mark S Roh; Linda H Colangelo; Michael J O'Connell; Greg Yothers; Melvin Deutsch; Carmen J Allegra; Morton S Kahlenberg; Luis Baez-Diaz; Carol S Ursiny; Nicholas J Petrelli; Norman Wolmark Journal: J Clin Oncol Date: 2009-09-21 Impact factor: 44.544
Authors: N Wolmark; J Bryant; R Smith; J Grem; C Allegra; D Hyams; J Atkins; N Dimitrov; R Oishi; D Prager; L Fehrenbacher; E Romond; L Colangelo; B Fisher Journal: J Natl Cancer Inst Date: 1998-12-02 Impact factor: 13.506
Authors: Stephen J Rulyak; Margaret T Mandelson; Teresa A Brentnall; Carolyn M Rutter; Edward H Wagner Journal: Gastrointest Endosc Date: 2004-02 Impact factor: 9.427
Authors: E Carter Paulson; Christine M Veenstra; Anil Vachani; Christine A Ciunci; Andrew J Epstein Journal: Cancer Date: 2015-06-16 Impact factor: 6.860
Authors: Hiroko Kunitake; Marcia M Russell; Ping Zheng; Greg Yothers; Stephanie R Land; Laura Petersen; Louis Fehrenbacher; Jeffery K Giguere; D Lawrence Wickerham; Clifford Y Ko; Patricia A Ganz Journal: J Cancer Surviv Date: 2016-08-25 Impact factor: 4.442
Authors: Melissa Y Carpentier; Sally W Vernon; L Kay Bartholomew; Caitlin C Murphy; Shirley M Bluethmann Journal: J Cancer Surviv Date: 2013-05-16 Impact factor: 4.442
Authors: Kelley M Kidwell; Greg Yothers; Patricia A Ganz; Stephanie R Land; Clifford Y Ko; Reena S Cecchini; Jacek A Kopec; Norman Wolmark Journal: Cancer Date: 2012-05-08 Impact factor: 6.860
Authors: Jada G Hamilton; Nancy Breen; Carrie N Klabunde; Richard P Moser; Bryan Leyva; Erica S Breslau; Sarah C Kobrin Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-10-09 Impact factor: 4.254
Authors: Beth A Glenn; Narissa J Nonzee; Ann S Hamilton; Lina Tieu; Annette E Maxwell; Catherine M Crespi; L Cindy Chang; Dennis Deapen; Roshan Bastani Journal: J Cancer Surviv Date: 2020-08-14 Impact factor: 4.442